Financial Performance - The company's revenue for Q1 2025 was ¥115,533,088.70, a decrease of 21.93% compared to ¥147,987,552.62 in the same period last year[5] - The net loss attributable to shareholders was ¥12,416,708.34, an improvement of 39.32% from a loss of ¥20,461,696.10 in the previous year[5] - Net profit for the period was a loss of ¥12,537,029.71, compared to a loss of ¥20,731,689.79 in the previous period, showing an improvement of approximately 40%[20] - The company reported a total asset of CNY 2,717,977,142.99 as of March 31, 2025, a slight decrease from CNY 2,736,124,198.16 at the beginning of the period[15] - Total operating revenue decreased to ¥115,533,088.70 from ¥147,987,552.62, a decline of approximately 22%[19] - Total operating costs reduced to ¥140,612,164.96 from ¥173,317,426.29, a decrease of about 19%[19] Cash Flow - The net cash flow from operating activities increased significantly by 831.46%, reaching ¥31,794,300.40 compared to ¥3,413,366.26 in the same period last year[5] - Cash flow from operating activities generated ¥31,794,300.40, significantly up from ¥3,413,366.26 in the previous period[21] - Cash flow from investment activities showed a net outflow of ¥5,598,162.05, an improvement from a net outflow of ¥12,308,817.04 in the previous period[21] - Net cash flow from financing activities was $1,431,099.46, a significant decrease from $106,889,610.07 in the previous period[22] - Cash inflows from financing activities totaled $93,300,000.00, down from $167,000,000.00 year-over-year[22] - Cash outflows for debt repayment amounted to $87,850,000.00, an increase from $56,100,000.00 in the previous period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,717,977,142.99, a slight decrease of 0.66% from ¥2,736,124,198.16 at the end of the previous year[5] - Current assets totaled CNY 705,046,116.30, showing a marginal increase from CNY 702,436,533.60[15] - The total liabilities decreased slightly to CNY 716,326,000.35 from CNY 721,802,602.07, reflecting a reduction of about 0.8%[16] - The company's equity remained stable at CNY 1,400,779,329.86, unchanged from the previous period[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,396, with the largest shareholder holding 32.89% of the shares[10] - The company's weighted average return on equity was -0.62%, an improvement from -0.98% in the previous year[5] Research and Development - Research and development expenses rose by 42% year-on-year, driven by the advancement of new projects and drug re-registration[11] - Research and development expenses increased to ¥8,201,323.83 from ¥5,779,375.24, representing a rise of about 42%[19] Regulatory and Compliance - The company has not received any conclusive opinions or decisions from the China Securities Regulatory Commission regarding the ongoing investigation[14] - The company will actively cooperate with the regulatory body during the investigation period[14] - The company has not audited its first-quarter report for 2025[23] - The new accounting standards will be implemented starting in 2025[23] Other Financial Metrics - The company reported a decrease in accounts receivable from CNY 120,099,455.35 to CNY 94,754,796.53, a decline of approximately 21.1%[15] - The company’s inventory decreased from CNY 106,799,072.77 to CNY 100,225,778.99, a reduction of about 6.2%[15] - The company recorded a 244% increase in other income, primarily from a significant VAT refund received this period[11] - The company reported a decrease in sales expenses to ¥39,291,462.43 from ¥49,164,808.86, a reduction of approximately 20%[19] - The company recorded an investment loss of ¥558,811.98, contrasting with a gain of ¥35,587.88 in the previous period[19] - The basic and diluted earnings per share improved to -0.0390 from -0.0643, indicating a reduction in loss per share[20] - Cash and cash equivalents increased to CNY 294,493,873.46 from CNY 270,419,234.88, representing an increase of approximately 8.0%[15] - Short-term borrowings rose significantly to CNY 115,109,694.44 from CNY 80,080,055.56, indicating a 43.7% increase[16] - Other cash outflows related to financing activities were $425,000.00, down from $1,161,083.39 year-over-year[22]

Financial Performance - The company's operating revenue for 2024 was approximately ¥569.71 million, a decrease of 1.66% compared to ¥579.33 million in 2023[19]. - The net profit attributable to shareholders for 2024 was approximately -¥87.40 million, showing an improvement of 6.09% from -¥93.07 million in 2023[19]. - The cash flow from operating activities for 2024 was approximately ¥50.15 million, a significant increase of 304.17% compared to -¥24.56 million in 2023[19]. - The total assets at the end of 2024 were approximately ¥2.74 billion, a decrease of 2.66% from ¥2.81 billion at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥2.01 billion, down 4.10% from ¥2.09 billion at the end of 2023[19]. - The basic earnings per share for 2024 was -¥0.2749, an improvement of 6.08% from -¥0.2927 in 2023[19]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, amounting to approximately -¥109.53 million in 2024, a decline of 6.24% from -¥103.10 million in 2023[19]. - The weighted average return on net assets for 2024 was -4.27%, slightly improved from -4.36% in 2023[19]. Revenue Breakdown - The company's total revenue for Q1 was approximately 148 million, Q2 was about 133 million, Q3 was around 121 million, and Q4 reached approximately 167 million[23]. - The revenue from self-manufactured oral solid preparations increased by 11.49% to ¥256,633,167.71, accounting for 45.05% of total revenue[61]. - The revenue from self-manufactured small volume injections decreased by 24.40% to ¥143,397,102.67, accounting for 25.17% of total revenue[61]. Cash Flow and Investments - Net cash flow from operating activities improved significantly to ¥50,146,536.51 in 2024, compared to a negative cash flow of ¥24,561,754.07 in 2023, an increase of 304.17%[77]. - Cash flow from investing activities showed a net inflow of ¥5,568,663.15 in 2024, a turnaround from a net outflow of ¥82,080,011.17 in 2023, an increase of 106.78%[77]. - Cash flow from financing activities increased significantly to ¥50,557,204.74 in 2024, compared to a negative cash flow of ¥11,203,509.75 in 2023, an increase of 551.26%[77]. - Total cash and cash equivalents increased by ¥106,272,404.40 in 2024, reversing a decrease of ¥117,845,274.99 in 2023, a change of 190.18%[77]. Research and Development - The company has established a specialized research platform for improved new drug development, enhancing its capabilities in traditional Chinese medicine and chemical drugs[38]. - The research and development model includes both independent and collaborative approaches, with partnerships established with several universities and research institutions[38]. - The company is currently developing several new products, including sodium bicarbonate injection and vitamin B6 injection, aimed at expanding its product line[74]. - R&D investment decreased to ¥22,752,050.49 in 2024 from ¥30,916,051.19 in 2023, a decline of 26.41%[75]. - R&D expenditure as a percentage of operating revenue fell to 3.99% in 2024 from 5.34% in 2023, a decrease of 1.35%[75]. Production and Quality Control - The company emphasizes quality control in production, adhering to national drug management laws and regulations[41]. - The company has implemented a comprehensive quality management system, ensuring all materials undergo strict quality inspections before production[43]. - The company has a strong focus on quality management, with Mr. Jiang Changhong serving as the Quality Management Department Head[141]. - The company has established a robust management team with a mix of academic and practical experience in the pharmaceutical industry[139]. Market and Strategic Initiatives - The company is focused on modernizing its pharmaceutical operations, integrating drug research, production, and sales[33]. - The company plans to enhance its marketing efforts and develop the "Tian Sheng Cloud" APP for internet pharmaceutical sales[57]. - The company is actively pursuing market expansion strategies to enhance its competitive position in the pharmaceutical industry[101]. - The company plans to launch its own internet pharmaceutical sales platform by 2025, leveraging AI tools to enhance sales and brand influence[45]. Governance and Compliance - The company maintained strict compliance with relevant laws and regulations, ensuring effective corporate governance and protecting investor interests[126]. - The company has established a market value management system and approved a valuation enhancement plan to improve its market standing[123]. - The company has a dedicated financial department that operates independently, ensuring sound financial management and decision-making[131]. - The company has established a robust internal audit system to enhance risk control and internal supervision[129]. Environmental Responsibility - The company has invested a total of 1.9336 million yuan in environmental protection during the reporting period, including 0.4992 million yuan for operation and maintenance of environmental facilities and 1.3353 million yuan for upgrading the wastewater treatment station[176]. - The company has implemented the "Three Simultaneities" principle for all construction projects, ensuring compliance with environmental impact assessments[168]. - The company has established an emergency response plan for environmental incidents, which has been reviewed by experts and aims to minimize environmental risks from accidents[175]. - The company has successfully managed its wastewater discharge, with all monitored pollutants reported as not exceeding the standards[170]. Social Responsibility - The company emphasizes its commitment to social responsibility, focusing on economic benefits while protecting the rights of stakeholders and participating in public welfare[178]. - The company provides monthly financial assistance of 1,000 yuan to a sick child in Chongqing, reducing the family's burden until the child graduates from university[182]. - The company has established a strategic partnership with local communities to promote rural revitalization through the development of traditional Chinese medicine resources[183]. Risk Management - The company recognizes R&D risks, including potential misalignment with market needs and regulatory challenges, and is focused on optimizing its R&D processes[117]. - The pharmaceutical industry faces significant policy risks, including stricter regulations and cost control measures, which could impact future development[115]. - The company is addressing drug price risks due to policy-driven price reductions and market competition by enhancing cost control and marketing strategies[119]. Shareholder Engagement - The company emphasizes the protection of shareholder rights, ensuring equal treatment for all shareholders, especially minority shareholders, during significant decision-making processes[179]. - The company actively engages with investors through various channels, including an investor hotline and performance briefings, to ensure transparent communication[179]. - The company held its annual general meeting on May 16, 2024, with a participation rate of 6.45% from investors[133].

证券代码：002872 证券简称：ST 天圣 公告编号：2025-017 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 一、关于实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易自 2019 年 6 月 5 日起被实施其他 风险警示。具体内容详见公司在指定信息披露媒体上刊登的《关于公司股票交 易被实行其他风险警示的公告》、《关于公司股票交易被实行其他风险警示相 关事项的进展公告》。 二、关于争取撤销其他风险警示所采取的措施及有关工作进展情况 1、公司进一步加强了董事、监事、高级管理人员及广大业务人员对相关法 律、法规、 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-016 天圣制药集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、基本情况 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召 开的第六届董事会第十次会议，以及 2025 年 3 月 10 日召开的 2025 年第一次 临时股东大会，审议通过了《关于修订<公司章程>的议案》，具体内容详见公 司 分 别 于 2025 年 2 月 22 日 、2025 年 3 月 11 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露的相关公告。 二、工商变更登记情况 近日，公司已完成了工商变更登记及《公司章程》备案手续，取得了重庆 市市场监督管理局换发的《营业执照》，公司本次《营业执照》的变更仅涉及 经营范围变更，其他事项不变，变更后的《营业执照》相关信息如下： 1、名称：天圣制药集团股份有限公司 8、经营范围：许可项目：药品生产；药品零售；药品进出口；药品委托 生产；药品批发；药品互联网信息服务； ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-015 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 一、关于实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易自 2019 年 6 月 5 日起被实施其他 风险警示。具体内容详见公司在指定信息披露媒体上刊登的《关于公司股票交 易被实行其他风险警示的公告》、《关于公司股票交易被实行其他风险警示相 关事项的进展公告》。 二、关于争取撤销其他风险警示所采取的措施及有关工作进展情况 1、公司进一步加强了董事、监事、高级管理人员及广大业务人员 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-014 （2）网络投票时间：其中，通过深圳证券交易所交易系统进行网络投票的 具体时间为：2025 年 3 月 10 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为：2025 年 3 月 10 日 9:15 至 15:00 期间的任意时间。 2、现场会议召开地点：重庆市渝北区创新经济走廊食品城西一街天圣制药 集团股份有限公司七楼会议室。 天圣制药集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会决议的情形。 一、会议召开的基本情况 1、会议召开时间 （1）现场会议时间：2025 年 3 月 10 日（星期一）下午 14:00 开始。 3、会议召集人：天圣制药集团股份有限公司（以下简称"公司"）第六届 董事会。 4、现场会议主持人：董事长刘爽先生。 5、会议召开方式：现场记名投票 ...

地址：北京市朝阳区光华路正大中心北塔 11-12 层 邮编：100020 电话：010-65876666 传真：010-65876666-6 北京中银律师事务所 关于天圣制药集团股份有限公司 2025 年第一次临时股东大会之 法律意见书 二〇二五年三月 法律意见书 北京中银律师事务所 关于天圣制药集团股份有限公司 2025 年第一次临时股东大会之 法律意见书 致：天圣制药集团股份有限公司 北京中银律师事务所（以下简称"本所"）接受天圣制药集团股份有限公司 （以下简称"公司"）的委托，指派见证律师出席公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"）进行法律见证，并依据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）、 《上市公司治理准则》（以下简称"《治理准则》"）等法律、法规和规范性文 件以及《天圣制药集团股份有限公司章程》（以下简称"《公司章程》"）的规 定就公司本次股东大会的召集、召开程序、出席会议人员的资格、表决程序、表 决结果等有关事宜出具法律意见书。 本所律师依据法律 ...

天圣制药集团股份有限公司 公司章程 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司治理准则》、《上市 公司章程指引》、《上市公司股东大会规则》、《中国共产党章程》和其他有 关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定，由重庆天圣制药有限公 司整体改制设立的股份有限公司（以下简称"公司"）。公司在重庆市工商行 政 管 理 局 注 册 登 记 ， 取 得 《 营 业 执 照 》 ， 统 一 社 会 信 用 代 码 为 9150000073397948XL。 第三条 公司于 2017 年 4 月 28 日经中国证券监督管理委员会（以下简称 "中国证监会"）核准，首次向社会公众发行人民币 5300 万股，于 2017 年 5 月 19 日在深圳证券交易所上市。 第四条 公司注册名称：天圣制药集团股份有限公司。 英文名称：Tiansheng Pharmaceutical Group Co., Ltd 第五条 公司住所：重庆市朝阳工业园区（垫江桂溪 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-011 | 非药品类易制毒化学品生产；第三类非药品 | 非药品类易制毒化学品生产；第三类非药品 | | --- | --- | | 类易制毒化学品经营；特殊医学用途配方食 | 类易制毒化学品经营；特殊医学用途配方食 | | 品销售；医学研究和试验发展；包装专用设 | 品销售；医学研究和试验发展；包装专用设 | | 备销售；医学研究和试验发展（除人体干细 | 备销售；医学研究和试验发展（除人体干细 | | 胞、基因诊断与治疗技术开发和应用）；健 | 胞、基因诊断与治疗技术开发和应用）；健 | | 康咨询服务（不含诊疗服务）；食用农产品 | 康咨询服务（不含诊疗服务）；食用农产品 | | 初加工；医护人员防护用品零售；医护人员 | 初加工；医护人员防护用品零售；医护人员 | | 防护用品批发；专用化学产品销售（不含危 | 防护用品批发；专用化学产品销售（不含危 | | 险化学品）；专用化学产品制造（不含危险 | 险化学品）；专用化学产品制造（不含危险 | | 化学品）；食用农产品批发；医护人员防护 | 化学品）；食用农产品批发；医护人员防护 | | ...

关于拟变更公司非职工代表监事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司 天圣制药集团股份有限公司（以下称"公司"）监事会于近日收到公司持 股 3%以上股东重庆渝垫国有资产经营集团有限公司（以下简称"渝垫国资"） 告知函，因余建伟先生职务调整，渝垫国资拟变更委派的监事人选，拟委派郭 炯杓先生担任公司第六届监事会非职工代表监事。原委派监事余建伟先生自公 司股东大会补选产生新任监事后不再担任公司监事职务，且不再担任公司及子 公司任何职务。截止本公告披露日，余建伟先生未持有公司股份。 公司及公司监事会对余建伟先生在担任公司监事期间的勤勉工作和为公司 规范运作所做出的贡献表示衷心感谢！ 证券代码：002872 证券简称：ST 天圣 公告编号：2025-012 2025 年 2 月 21 日 1 附件：郭炯杓先生简历 郭炯杓，男，中国国籍，汉族，1985 年出生，中共党员，本科学历，政工 师。历任垫江县兴渝城市建设有限责任公司综合部副部长；历任重庆渝垫国有 资产经营集团有限公司综合部主办、党群工作部主办。现任重庆渝垫国有资产 经营集团 ...